Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinson's Disease
Posted on: Thursday, 22 January 2009, 10:12 CST
Study Recruiting Adult Parkinson's Patients with Behavioral Changes
ACADIA Pharmaceuticals, a biopharmaceutical company headquartered in
ACADIA Pharmaceuticals is now evaluating an investigational medication that researchers hope will help treat the cognitive and behavioral changes caused by Parkinson's. As Parkinson's disease progresses, up to 40 percent of patients can experience what is called 'Parkinson's Psychosis.' A condition in which patients experience changes in thought, behavior and judgment that can have devastating effects. In more advanced stages these symptoms include hallucinations, illusions and delusions where patients see things that aren't really there, believe things that are untrue, create false ideas and falsely accuse those closest to them.
"While the physical manifestations of Parkinson's disease are difficult to deal with, the changes in thought, behavior and judgment strain the bonds between patients and their caregivers and families," said expert Dr.
An online survey conducted by MediciGlobal, a firm assisting ACADIA Pharmaceuticals in finding Parkinson's patients with Psychosis for this study, found that 4 out of every 10 Parkinson's caregivers were unaware that these behavioral and cognitive changes were associated with Parkinson's.
There are currently no FDA-approved treatments for these particular non-physical symptoms of Parkinson's disease. Research is necessary to advance future medicines for Parkinson's Psychosis.
Those caring for someone who may be experiencing Parkinson's Disease Psychosis, are encouraged to call the toll-free study hotline , at 1-866-565-0261 or visit the clinical research Web site at www.ParkinsonsMindStudy.com. Here caregivers can find clinical research centers conducting this study.
SOURCE MediciGlobal
Source: PR Newswire
Related Articles
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Valeant Pharmaceuticals Announces the Launch of the zelaCARD for Parkinson's Disease Patients Taking Zelapar(R)
- Parkinson's Disease Dementia is Studied
- Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- New Study of Depressive Symptoms in Parkinson's Disease Patients Shows Positive Results for Mirapex
- Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
- New Study Shows Medication May Help Parkinson's Disease Patients Who Suffer From Dementia
- New Study in the New England Journal of Medicine Shows Exelon May Help Parkinson's Disease Patients Who Suffer From Dementia
- New Study Data in December 9th New England Journal of Medicine Shows Medication May Help Parkinson's Disease Patients With Dementia
- AGILECT(R) Improved Parkinson's Disease Symptoms Without Worsening Cognitive and Behavioral Symptoms
User Comments (0)

RSS Feeds